Gastrointestinal tumours 2
Invited discussant abstracts 144O and 145O
Date
20 Dec 2015Session
Gastrointestinal tumours 2Presenters
Kei MuroAuthors
K. MuroAuthor affiliations
- Clinical Oncology, Aichi Cancer Center Hospital, 464-8681 - Nagoya/JP
Resources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
View the abstracts discussed:
- Comparison of efficacy and safety of paclitaxel and capecitabine followed by capecitabine as maintenance therapy versus cisplatin and capecitabine therapy for advanced gastric cancer: a multicentre, randomised, active-controlled phase III study
- Phase II study of AZD4547 in FGFR amplified tumours: gastroesophageal cancer (GC) cohort clinical and translational results
Resources from the same session
1025 - RADIANT-4: Efficacy and safety of everolimus in advanced, nonfunctional neuroendocrine tumors (NET) of the lung or gastrointestinal (GI) tract
Presenter: James Yao
Session: Gastrointestinal tumours 2
Resources:
Abstract
1096 - Phase II study of AZD4547 in FGFR amplified tumours: gastroesophageal cancer (GC) cohort clinical and translational results
Presenter: Elizabeth Smyth
Session: Gastrointestinal tumours 2
Resources:
Abstract
Slides
Webcast
Invited discussant abstract 134O
Presenter: Sun Young Rha
Session: Gastrointestinal tumours 2
Resources:
Slides
Webcast
599 - Comparison of efficacy and safety of paclitaxel and capecitabine followed by capecitabine as maintenance therapy versus cisplatin and capecitabine therapy for advanced gastric cancer: a multicentre, randomised, active-controlled phase III study
Presenter: Xiaotian Zhang
Session: Gastrointestinal tumours 2
Resources:
Abstract
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.